Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

Table 3 Multivariable analysis for the risk factors of EBV and CMV infections post-transplantation

Parameters	HR	95% CI	P value
EBV-DNAemia
EBV serostatus: D- /R+ vs other	2.142	0.956–4.797	0.064
ATG use in the conditioning: ATG vs no ATG^#	4.408	1.967–9.878	*<0.001
EBV-associated disease
ATG use in the conditioning: ATG vs no ATG^#	3.235	1.078–9.711	*0.036
CMV-DNAemia
CR status at transplant: ≥ CR2 vs CR1	1.222	0.931–1.603	0.149
ATG use in the conditionin: ATG vs no ATG^#	2.797	1.783–4.387	*<0.001
Sorafenib pre-transplant: use vs no use	1.340	0.910–1.974	0.138
aGVHD^&	1.641	1.067–2.522	*0.024
CMV-associated disease
aGVHD^&	3.179	1.175–8.601	*0.023

Abbreviations: EBV Epstein-Barr virus, D donor, R recipient, ATG antithymocyte immunoglobulin, CMV cytomegalovirus, CR complete remission, CR2 second CR, CR1 first CR, aGVHD acute graft-versus-host disease, HR hazard ratio, CI confidence interval. *P<0.05; ^# All patients undergoing haploidentical donor (HID)/HLA-matched unrelated donor (MUD) transplants received ATG as GVHD prophylaxis, and none of those undergoing HLA-matched sibling donor (MSD) transplants received ATG as GVHD prophylaxis. Considering there was collinearity between transplant modality (HID/MUD vs MSD) and ATG use in the conditioning (ATG vs no ATG), we only included ATG use in the conditioning in the analysis of risk factors for EBV/CMV infections. ^&Time-dependent covariate

ISSN: 1741-7015